Harrow Announces Availability of Fortisite Formulations for In-Office Use

Harrow announced the availability, for in-office use, of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations in solution.

According to Harrow, the availability of Fortisite for in-office use represents the first time eye care professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients.

ImprimisRx offers a Fortisite patient access program and a 100% replacement guarantee for any expired 503B Fortisite product, ensuring all prescribing US eye care professionals can continuously stock Fortisite formulations in their offices. Eye care professionals can order Fortisite online or call ImprimisRx customer care at (844) 446-6979.

“The availability of Fortisite formulations will provide eye care professionals with new and important tools in their pharmaceutical armamentarium as they consider how to treat potentially sight-threatening infections," Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said in a news release. "Until there is an FDA-approved product to meet these needs, Fortisite formulations have the potential to become the standard of care for ophthalmology and optometry practices across the country.

“Because Fortisite is now available for in-office use from our FDA-registered 503B outsourcing facility, each bottle must strictly adhere to rigorous analytical testing protocols that are not required for locally regulated 503A compounding pharmacies," Mr. Baum said. 

Comments from eyecare professionals regarding Fortisite (none of whom are consultants to Harrow):

Compounded medications are not reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products.